NOVO NORDISK INC.

Lobbying for NOVO NORDISK INC.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $2,330,000.00 expenses · posted Apr 18, 2025

Official filing document

Bills named in this filing 1

S 150
Affordable Prescriptions for Patients Act of 2023

Lobbying activity 4

Health Issues

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding

Budget/Appropriations

Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding

Medicare/Medicaid

Obesity, Treat and Reduce Obesity Act, IRA implementation

S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.